文献速递心脏核医学放射性药物与辐射防护

基质金属蛋白酶靶向示踪剂RYM1用于动脉瘤成像的临床前评估

Preclinical Evaluation of RYM1, a Matrix Metalloproteinase-Targeted Tracer for Imaging Aneurysm.
PubMed 文献 · J Nucl Med · 2017-03-30

本研究开发了基于亲水性两性离子基质金属蛋白酶抑制剂RYM的新型泛基质金属蛋白酶示踪剂RYM1,并用99mTc标记,在动脉瘤小鼠模型中与常用泛基质金属蛋白酶示踪剂RP805进行比较。99mTc-RYM1放射化学性质稳定、经肾脏快速清除、血本底低于99mTc-RP805,在血管紧张素II灌注的载脂蛋白E缺陷小鼠中,动脉瘤对99mTc-RYM1的摄取高于非扩张主动脉,且与主动脉基质金属蛋白酶活性和CD68表达相关。

要点

  • 99mTc-RYM1在小鼠血液中放射化学稳定达5小时,经肾脏快速清除。
  • 在颈动脉瘤模型中,放射自显影显示99mTc-RYM1与动脉瘤结合并具有特异性。
  • 血管紧张素II灌注4周后36%(4/11)存活小鼠形成腹主动脉瘤,瘤体摄取高于非扩张主动脉。

核心结论

  • 新开发的泛基质金属蛋白酶抑制剂示踪剂99mTc-RYM1具有适合早期血管成像的药代动力学,能够特异性检测动脉瘤中的炎症和基质金属蛋白酶活性。

研究设计与样本

  • 合成基于大环异羟肟酸的泛基质金属蛋白酶抑制剂RYM1,并用99mTc标记。
  • 用放射性高效液相色谱分析99mTc-RYM1的放射化学稳定性。
  • 在C57BL/6J小鼠(n=10)中比较99mTc-RYM1与99mTc-RP805的血液动力学和生物分布。
  • 在氯化钙诱导颈动脉瘤的载脂蛋白E缺陷小鼠(n=11)中,用定量放射自显影评估99mTc-RYM1与动脉瘤的结合及特异性。
  • 在血管紧张素II灌注的载脂蛋白E缺陷小鼠(n=16)中进行小动物SPECT/CT成像。

主要发现

  • RYM1对多种基质金属蛋白酶显示纳摩尔级抑制常数。
  • 99mTc-RYM1在小鼠血液中放射化学稳定5小时,体内经肾脏快速清除,且血中水平低于99mTc-RP805。
  • 放射自显影显示99mTc-RYM1与颈动脉瘤结合并具有特异性。
  • 血管紧张素II灌注载脂蛋白E缺陷小鼠4周后,36%(4/11)存活动物形成腹主动脉瘤。
  • 体内99mTc-RYM1小动物SPECT/CT图像显示腹主动脉瘤摄取高于非扩张主动脉,且主动脉摄取与主动脉基质金属蛋白酶活性和CD68表达相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Matrix metalloproteinases (MMPs) play a key role in abdominal aortic aneurysm (AAA) development. Accordingly, MMP-targeted imaging provides important information regarding vessel wall biology in the course of aneurysm development. Given the small size of the vessel wall and its proximity with blood, molecular imaging of aneurysm optimally requires highly sensitive tracers with rapid blood clearance. To this end, we developed a novel hydrosoluble zwitterionic MMP inhibitor, RYM, on the basis of which a pan-MMP tracer, RYM1, was designed. Here, we describe the development and preclinical evaluation of RYM1 in comparison with RP805, a commonly used pan-MMP tracer in murine models of aneurysm. Methods: The macrocyclic hydroxamate-based pan-MMP inhibitor coupled with 6-hydrazinonicotinamide, RYM1, was synthesized and labeled with 99mTc. Radiochemical stability of 99mTc-RYM1 was evaluated by radio-high-performance liquid chromatography analysis. Tracer blood kinetics and biodistribution were compared with 99mTc-RP805 in C57BL/6J mice (n = 10). 99mTc-RYM1 binding to aneurysm and specificity were evaluated by quantitative autoradiography in apolipoprotein E-deficient (apoE-/-) mice with CaCl2-induced carotid aneurysm (n = 11). Angiotensin II-infused apoE-/- (n = 16) mice were used for small-animal SPECT/CT imaging. Aortic tissue MMP activity and macrophage marker CD68 expression were assessed by zymography and reverse-transcription polymerase chain reaction. Results: RYM1 showed nanomolar range inhibition constants for several MMPs. 99mTc-RYM1 was radiochemically stable in mouse blood for 5 h and demonstrated rapid renal clearance and lower blood levels in vivo compared with 99mTc-RP805. 99mTc-RYM1 binding to aneurysm and its specificity were shown by autoradiography in carotid aneurysm. Angiotensin II infusion in apoE-/- mice for 4 wk resulted in AAA formation in 36% (4/11) of surviving animals. In vivo 99mTc-RYM1 small-animal SPECT/CT images showed higher uptake of the tracer in AAA than nondilated aortae. Finally, aortic uptake of 99mTc-RYM1 in vivo correlated with aortic MMP activity and CD68 expression. Conclusion: The newly developed pan-MMP inhibitor-based tracer 99mTc-RYM1 displays favorable pharmacokinetics for early vascular imaging and enables specific detection of inflammation and MMP activity in aneurysm.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Toczek J, Ye Y, Gona K, et al. Preclinical Evaluation of RYM1, a Matrix Metalloproteinase-Targeted Tracer for Imaging Aneurysm. J Nucl Med. 2017. PMID: 28360209. doi:10.2967/jnumed.116.188656

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。